These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 23988873)

  • 41. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.
    Loganayagam A; Arenas-Hernandez M; Fairbanks L; Ross P; Sanderson JD; Marinaki AM
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):403-6. PubMed ID: 19795123
    [TBL] [Abstract][Full Text] [Related]  

  • 42. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
    Yang CG; Ciccolini J; Blesius A; Dahan L; Bagarry-Liegey D; Brunet C; Varoquaux A; Frances N; Marouani H; Giovanni A; Ferri-Dessens RM; Chefrour M; Favre R; Duffaud F; Seitz JF; Zanaret M; Lacarelle B; Mercier C
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):49-56. PubMed ID: 20204365
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
    Deenen MJ; Tol J; Burylo AM; Doodeman VD; de Boer A; Vincent A; Guchelaar HJ; Smits PH; Beijnen JH; Punt CJ; Schellens JH; Cats A
    Clin Cancer Res; 2011 May; 17(10):3455-68. PubMed ID: 21498394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare
    van Kuilenburg ABP; Pleunis-van Empel MCH; Brouwer RB; Sijben AEJ; Knapen DG; Oude Munnink TH; van Zanden JJ; Janssens-Puister J; Dobritzsch D; Meinsma R; Meijer-Jansen J; van Dooren SJM; Vijzelaar R; Pop A; Salomons GS; Maring JG; Niezen-Koning KE
    JCO Precis Oncol; 2024 May; 8():e2300599. PubMed ID: 38709992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
    Stavraka C; Pouptsis A; Okonta L; DeSouza K; Charlton P; Kapiris M; Marinaki A; Karapanagiotou E; Papadatos-Pastos D; Mansi J
    Breast Cancer Res Treat; 2019 Jun; 175(2):511-517. PubMed ID: 30746637
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
    Loriot MA; Masskouri F; Carni P; Le Malicot K; Seitz JF; Michel P; Legoux JL; Bouché O; André T; Faroux R; Delaloge S; Malka D; Guigay J; Thariat J; Thomas F; Barin-Le-Guellec C; Ciccolini J; Boyer JC; Étienne-Grimaldi MC
    Bull Cancer; 2019 Sep; 106(9):759-775. PubMed ID: 31253356
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Phenotype- or genotype test for dihydropyrimidin dehydrogenase deficiency before treatment with a fluoropyrimidine].
    Andersen SE; Paulsen NH; Pfeiffer P; Qvortrup C; Damkier P
    Ugeskr Laeger; 2021 Feb; 183(6):. PubMed ID: 33570023
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
    Coursier S; Martelet S; Guillermet A; Emptoz J; Villier C; Bontemps H
    Gastroenterol Clin Biol; 2010 Mar; 34(3):218-23. PubMed ID: 20219304
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
    Kanai M; Kawaguchi T; Kotaka M; Manaka D; Hasegawa J; Takagane A; Munemoto Y; Kato T; Eto T; Touyama T; Matsui T; Shinozaki K; Matsumoto S; Mizushima T; Mori M; Sakamoto J; Ohtsu A; Yoshino T; Saji S; Matsuda F
    Cancer Med; 2023 Apr; 12(7):7808-7814. PubMed ID: 36524458
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unanticipated toxicity to capecitabine.
    Moore S
    Oncol Nurs Forum; 2009 Mar; 36(2):149-52. PubMed ID: 19273404
    [No Abstract]   [Full Text] [Related]  

  • 51. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
    Lau DK; Fong C; Arouri F; Cortez L; Katifi H; Gonzalez-Exposito R; Razzaq MB; Li S; Macklin-Doherty A; Hernandez MA; Hubank M; Fribbens C; Watkins D; Rao S; Chau I; Cunningham D; Starling N
    BMC Cancer; 2023 Apr; 23(1):380. PubMed ID: 37101114
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
    De Luca O; Salerno G; De Bernardini D; Torre MS; Simmaco M; Lionetto L; Gentile G; Borro M
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430399
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
    Shahrokni A; Rajebi MR; Harold L; Saif MW
    JOP; 2009 Mar; 10(2):215-20. PubMed ID: 19287123
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Near Miss or Standard of Care?
    Winquist LE; Sanatani M; Kim RB; Winquist E
    Curr Oncol; 2020 Dec; 28(1):94-97. PubMed ID: 33704179
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
    Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
    Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Implementation and clinical benefit of DPYD genotyping in a Danish cancer population.
    Paulsen NH; Pfeiffer P; Ewertz M; Fruekilde PBN; Feddersen S; Holm HS; Bergmann TK; Qvortrup C; Damkier P
    ESMO Open; 2023 Feb; 8(1):100782. PubMed ID: 36791638
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population.
    Saarenheimo J; Wahid N; Eigeliene N; Ravi R; Salomons GS; Ojeda MF; Vijzelaar R; Jekunen A; van Kuilenburg ABP
    Cancer Chemother Pharmacol; 2021 May; 87(5):657-663. PubMed ID: 33544210
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase.
    Falvella FS; Caporale M; Cheli S; Martinetti A; Berenato R; Maggi C; Niger M; Ricchini F; Bossi I; Di Bartolomeo M; Sottotetti E; Bernardi FF; de Braud F; Clementi E; Pietrantonio F
    Int J Mol Sci; 2015 Apr; 16(4):8884-95. PubMed ID: 25906475
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase.
    Del Re M; Restante G; Di Paolo A; Crucitta S; Rofi E; Danesi R
    Curr Pharm Des; 2017; 23(14):2028-2034. PubMed ID: 28128059
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.
    Blasco H; Boisdron-Celle M; Bougnoux P; Calais G; Tournamille JF; Ciccolini J; Autret-Leca E; Le Guellec C
    Br J Clin Pharmacol; 2008 Jun; 65(6):966-70. PubMed ID: 18294332
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.